UNC Lead Academic Participating Site

Lineberger综合癌症中心（Lineberger Comprehensive Cancer Center）寻求继续作为领先的学术机构， 国家临床试验网络（NCTN）的参与网站。LCCC是唯一一个被指定的公共NCI 北卡罗来纳州的一家综合性癌症中心，致力于改善癌症患者的预后。 成长状态在2015年的最新审查中，NCI将其评为“卓越”，癌症治疗费用为2.33亿美元- 相关的校外资金，EMLCCC有一个杰出的临床/转化研究计划，包括 集中的临床试验办公室，辅以高度参与的翻译部门。学术带头人 参与研究中心（LAPS）应用程序反映了我们的临床研究计划目标，即通过以下方式改善癌症治疗： 开展改变实践的临床试验，促进研究，为下一代临床研究提供信息。 审判作为少数几个接受所有临床研究的中心之一， 在上一个资助周期中获得了三项具有竞争力的NCI临床研究奖（NCTN LAPS奖，三中心UM 1 资助参与实验治疗药物临床试验网络（ETCTN）和NCTN综合 技术科学中心（ITSC）奖）。国家临床试验网络（NCTN）领导学术 参与的研究中心计划实现以下目标：（1）提供科学领导， 智力投入到创造周到的，可行的试验，以改善癌症患者的健康;（2） 通过我们不断发展的临床业务，以稳健的收益支持NCTN试验;以及（3）提供机会 优秀的转化科学嵌入并通知NCTN试验。

UNC Lineberger Comprehensive Cancer Center (UNC LCCC) seeks to continue to serve as a Lead Academic Participating Site for the National Clinical Trials Network (NCTN). UNC LCCC is the only public NCI-designated comprehensive cancer center in North Carolina, dedicated to improving outcomes of cancer patients across this growing state. Ranked “Exceptional” by the NCI at the most recent review in 2015 and with $233M in cancer- related extramural funding, UNC LCCC has an outstanding Clinical/Translational Research Program including a centralized clinical trials office complemented by a highly engaged translational component. This Lead Academic Participating Site (LAPS) application mirrors our clinical research program goal to improve cancer treatment by conducting practice-changing clinical trials and fostering research that will inform the next generation of clinical trials. UNC LCCC’s national stature in clinical research is illustrated by being one of a few centers to receive all three competitive NCI clinical research awards in the last funding cycle (an NCTN LAPS award, a tri-center UM1 grant for participation in the Experimental Therapeutics Clinical Trials Network (ETCTN) and an NCTN Integrated Technology Science Center (ITSC) award). As a National Clinical Trials Network (NCTN) Lead Academic Participating Site, UNC LCCC plans to accomplish the following aims: (1) To provide scientific leadership and intellectual input into the creation of thoughtful, feasible trials to improve the health of cancer patients; (2) To support NCTN trials with robust accrual through our growing clinical enterprise; and (3) To provide opportunities for excellent translational science embedded into and informing NCTN trials.